0001209191-21-028741.txt : 20210427
0001209191-21-028741.hdr.sgml : 20210427
20210427204556
ACCESSION NUMBER: 0001209191-21-028741
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210225
FILED AS OF DATE: 20210427
DATE AS OF CHANGE: 20210427
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Duraibabu Prathyusha
CENTRAL INDEX KEY: 0001779092
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30171
FILM NUMBER: 21861041
MAIL ADDRESS:
STREET 1: C/O SANGAMO THERAPEUTICS, INC.
STREET 2: 501 CANAL BLVD.
CITY: RICHMOND
STATE: CA
ZIP: 94804
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC
CENTRAL INDEX KEY: 0001001233
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 680359556
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7000 MARINA BLVD
CITY: BRISBANE
STATE: CA
ZIP: 94005
BUSINESS PHONE: 5109706000
MAIL ADDRESS:
STREET 1: 7000 MARINA BLVD
CITY: BRISBANE
STATE: CA
ZIP: 94005
FORMER COMPANY:
FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC
DATE OF NAME CHANGE: 20000208
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0306
4/A
2021-02-25
2021-03-01
0
0001001233
SANGAMO THERAPEUTICS, INC
SGMO
0001779092
Duraibabu Prathyusha
C/O SANGAMO THERAPEUTICS, INC.
7000 MARINA BLVD
BRISBANE
CA
94005
0
1
0
0
VP, PFO and PAO
Common Stock
2021-02-25
4
F
0
1863
11.19
D
27385
D
Common Stock
2021-02-25
4
A
0
13750
0.00
A
41135
D
Stock Option (Right to Buy)
11.19
2021-02-25
4
A
0
27500
0.00
A
2031-02-24
Common Stock
27500
27500
D
Represents shares underlying the portion of restricted stock unit ("RSU") grant that vested on February 25, 2021 which were surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on February 25, 2021 of $11.19/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended").
Includes: (a) 2,000 shares of common stock and 645 shares of common stock acquired by the Reporting Person on April 30, 2020 and October 30, 2020 respectively under the Issuer's 2010 Employee Stock Purchase Plan, as amended; (b) 3,637 shares resulting from the February 25, 2021 vesting of the Reporting Person's February 25, 2020 RSU grant and 11,000 shares subject to such RSU grant that will vest in two remaining annual installments of 5,499 shares and 5,501 shares on February 25, 2022 and 2023 respectively;
(c) 3,833 shares subject to the Reporting Person's April 25, 2019 grant that will vest in two remaining annual installments of 1,916 shares and 1,917 shares on April 25, 2021 and 2022 respectively; and (d) 3,000 shares subject to the Reporting Person's March 25, 2020 RSU grant that will vest in three annual installments of 1,000 shares on each of March 25, 2021, 2022 and 2023 respectively. The vesting of all such RSUs is subject to the Reporting Person's continued service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended
Represents 13,750 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2021 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended.
This Form 4/A is being filed solely to correct the stated amount included in Footnote 4 on the Form 4 filed on behalf of the Reporting Person on March 1, 2021 to be 13,750 shares subject to RSUs vesting which was erroneously reported to be 44,000 shares in such Footnote 4.
One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of Continuous Service, as defined in the 2018 EIP, as amended, by the Reporting Person measured from the February 25, 2021 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through each such vesting date, and subject to acceleration as provided in the 2018 EIP, as amended.
/s/ Matthew Colvin, Attorney-in-Fact for Prathyusha Duraibabu
2021-04-27